Currently Viewing:
Evidence-Based Oncology August 2014
ASCO's Initiative to Define Value In Cancer Care
Richard L. Schilsky, MD, Chief Medical Officer, ASCO
AJMC Panel Asks: Does it Pay to Use Pathways?
Written by Mary K. Caffrey; Produced by Nicole Beagin
Currently Reading
WellPoint Initiative May Challenge Some Practices
Mary K. Caffrey
AJMC Panel: Advances in Multiple Myeloma Therapy Extend Survival for Patients, Raising Cost Concerns
Written by Mary K. Caffrey, Produced by Nicole Beagin
MMRF Efforts Attack the Disease From Every Angle; "Transformation" on the Horizon
Mary K. Caffrey
How Do You Establish Value in Cancer Care?
Surabhi Dangi-Garimella, PhD
Reducing Risk and Improving Efficacy of Clinical Trials: the Adaptive Design
Surabhi Dangi-Garimella, PhD
Studies See Value of Prostate Cancer Diagnostic Test, but Will CMS Pay for It?
Mary K. Caffrey
Digital Technologies Gain Popularity for Smoking Cessation: Evidence Strongly Supports Some
Milly Dawson, MS, MPH
A New Method to Fight Cancer: The Body's Own Immune System
Surabhi Dangi-Garimella, PhD
FDA Moves to Regulate Thousands of Diagnostic Tests
Mary K. Caffrey
Robotic-Assisted Surgery: A Question of Value
Stanton R. Mehr and Marj P. Zimmerman, BSPharm, MS
In New Jersey, Focus in Fight Against Cancer Changes, and Care Comes Closer to Home
Mary K. Caffrey
A Glimpse Into Managed Care of Diagnostics
Mary K. Caffrey
Patient-Centered Physician Selection: A Necessary First Step for Accountable Care
Brian W. Powers, BA, and Sachin H. Jain, MD, MBA

WellPoint Initiative May Challenge Some Practices

Mary K. Caffrey
The insurer WellPoint made news in late May when it promised to pay $350 per month per patient to those oncologists who adhered to its cancer care clinical pathways.1 While the use of pathways is not new, this particular incentive appears to be a game changer, albeit one that not all think is a good idea.

Smaller oncology practices, which already face competitive disadvantages under healthcare reform, will struggle if they must keep track of multiple pathways for different insurers, said Ted Okon, executive director of the Community Oncology Alliance. “The idea that each payer has a different pathway is not sustainable; it’s totally unworkable,” he said. Okon told Evidence-Based Oncology he was aware of a practice that now has 5 different pathways it must track; WellPoint’s program alone includes protocols for breast, lung, and colorectal cancer.

The WellPoint program, which began July 1, 2014, in Kentucky, Indiana, Missouri, Wisconsin, Ohio, and Georgia, will expand nationwide throughout 2015.1 The initiative follows the release of studies over the past 2 years that show pathways can help reduce costs without harming the quality of care. In May 2013, Evidence-Based Oncology published a study by Cardinal Health Specialty Solutions, with Bruce A. Feinberg, DO, as the lead author, that showed an oncology pathways program could trim cancer care costs by 15% and reduce hospital admissions by 7%.2 More recently, UnitedHealth announced results from a 3-year pilot study involving 810 patients that produced a 34% reduction in cancer care costs. The study was published in the Journal of Oncology Practice.3,4

But because pathways seek to narrow treatment options beyond guidelines published by the National Comprehensive Cancer Network, the prospect of every health plan having its own protocols for reimbursement has unsettled some oncologists, especially those outside major hospital systems. Community oncologists lack the infrastructure to juggle multiple pathways protocols, Okon said, and he warned that this trend could be “another nail in the coffin” of community care. Meanwhile, other studies show that cancer drug costs, which are a prime target of savings in pathways, soar if the patient is treated in a hospital or hospital-owned clinic instead of a community practice.5

“I understand WellPoint’s drive toward trying to get a handle on costs,” Okon said. However, he said, “Pathways are not a panacea. They are a tool.” If too much judgment is taken from individual physicians, “It’s a slippery slope to a regimented formulary.”

Okon warned that with the onset of the Affordable Care Act, there are multiple pressures on community oncologists. Because many newly insured selected the lower-cost silver or bronze plans, pressure will mount to use narrow networks and formularies to control the costs of care. “We’ve only seen the tip of the iceberg,” he said. EBO
References

1. WellPoint’s new quality initiative aims to improve cancer outcomes, promote access to evidencebased and cost-effective care [press release]. Business Wire: Indianapolis, IN; May 28, 2014. http://ir.wellpoint.com/phoenix.zhtml?c=130104&p=irol-newsArticle&ID=1934999&highlight=.

2. Feinberg BA, Milligan S, Cooper J, et al. Third-party validation of observed savings from an oncology pathways program. Am J Manag Care. 2013;19(SP4): SP153-SP157.

3. Study: new cancer care payment model reduced health care costs, maintained outcomes [press release]. Minnetonka, MN: UnitedHealth Group; July 8, 2014. http://www.unitedhealthgroup.com/Newsroom/Articles/Feed/UnitedHealthcare/2014/0708CancerCarePaymentStudy.aspx.

4. Newcomer L., Gould B, Page RD, Donelan SA, Perkins M. Changing physician incentives for affordable, quality cancer care: results of an episode payment model [published online July 8, 2014]. J Oncol Pract. doi:JOP.2014.001488.

5. Rabin RC. Chemo costs in US driven higher by shift to hospital outpatient facilities. Kaiser Health News. http://capsules.kaiserhealthnews.org/?p=28074. Published May 6, 2014. Accessed August 4, 2014.
PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up